Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-U.S. Tech 100 Index (ASHUSTC)
4/29/2026, 12:00:00 AM
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
Korean Translation
자체 개발 1등급 혁신 신약 HS-10522 정제에 대해 중국 국가약품감독관리국(NMPA)으로부터 두 건의 임상시험 승인을 획득함. 해당 임상시험은 조절되지 않는 고혈압 및 원발성 알도스테론증 치료를 위한 것임.
Related Recent Events
Alphabet Inc (GOOGL) · Other
Ex-dividend date (2026-06-08) for a quarterly cash dividend of $0.22 per share, representing a 5% increase from the prior dividend. The dividend was declared on April 27, 2026 and is payable on June 15, 2026. A 1-2% price impact is estimated as dividend increases are generally viewed positively by the market, scheduled.
6/8/2026, 12:00:00 AM
Sunny Optical Technology Group Co Ltd (2382) · Other
Ex-dividend date on 2026-06-05 for the proposed final dividend of HKD 1.206 per share for the 2025 fiscal year. This standard corporate action is estimated to have a >1% price impact, scheduled.
6/5/2026, 12:00:00 AM
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release scheduled. Medium importance justified by anticipation of key financial performance data.
6/4/2026, 12:00:00 AM
JL mag Rare-Earth Co Ltd (6680) · Other
Ex-dividend date for the 2025 final dividend of RMB 2.2 per 10 shares on June 3, 2026. Payment is scheduled for June 26, 2026, scheduled.
6/3/2026, 12:00:00 AM
Time Interconnect Technology Ltd (1729) · Other
Annual General Meeting for 2026-05-29 scheduled.
5/29/2026, 12:00:00 AM
Kuaishou Technology (1024) · Earnings Release
Kuaishou Technology is expected to announce its first quarter 2026 financial results on May 27, 2026. Analysts forecast revenue and adjusted profit to be in line with market consensus, and the event is expected to cause over 10% price volatility expected.
5/27/2026, 12:00:00 AM